Xiaoran Huang

Xiaoran Huang

Auto-generated profile, based on publicly available information

Xiaoran Huang

Department of Emergency Medicine, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in European Heart Journal
Verified
Journal Article
Closed access
KYKehui Yang
Kehui Yang
JRJun Ren
Jun Ren
XLXin Li
Xin Li
ZWZheng Wang
Zheng Wang
LXLi Xue
Li Xue
FXFeng Xu
Feng Xu
Aims: Aortic aneurysm/dissection (AAD) is a life-threatening disorder lacking effective pharmacotherapeutic remedies. Aldehyde dehydrogenase 2 (ALDH2) polymorphism is tied with various risk factors for AAD including hypertension, atherosclerosis, and hypercholesterolaemia although direct correlation between the two remains elusive. Methods and results: Two independent case–control studies were conducted involving 307 AAD patients and 399 healthy controls in two geographically distinct areas in China. Our data revealed that subjects carrying mutant ALDH2 gene possessed a ∼50% reduced risk of AAD compared with wild-type (WT) alleles. Using 3-aminopropionitrile fumarate (BAPN)- and angiotensin II (Ang II)-induced AAD animal models, inhibition of ALDH2 was found to retard development of AAD. Mechanistically, ALDH2 inhibition ablated pathological vascular smooth muscle cell (VSMC) phenotypical switch through interaction with myocardin, a determinant of VSMC contractile phenotype. Using microarray and bioinformatics analyses, ALDH2 deficiency was found to down-regulate miR-31-5p, which further altered myocardin mRNA level. Gain-of-function and loss-of-function studies verified that miR-31-5p significantly repressed myocardin level and aggravated pathological VSMC phenotypical switch and AAD, an effect that was blunted by ALDH2 inhibition. We next noted that ALDH2 deficiency increased Max expression and decreased miR-31-5p level. Moreover, ALDH2 mutation or inhibition down-regulated levels of miR-31-5p while promoting myocardin downstream contractile genes in the face of Ang II in primary human VSMCs. Conclusions: ALDH2 deficiency is associated with a lower risk of AAD in patients and mice, possibly via suppressing VSMC phenotypical switch in a miR-31-5p-myocardin-dependent manner. These findings favour a role for ALDH2 and miR-31-5p as novel targets for AAD therapy.


25 November 2025 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Closed access
CMCong Mai
Cong Mai
XZXiaoxuan Zhong
Xiaoxuan Zhong
XHXiaoran Huang
Xiaoran Huang
HCHuan Cheng
Huan Cheng
HWHuifang Wang
Huifang Wang
XLXin Li
Xin Li
Sepsis-induced brain dysfunction (SIBD), a critical determinant of mortality and long-term neurological sequelae in sepsis patients. The mechanistic understanding of SIBD has been limited by conventional single-modality approaches, which fail to capture the complex oxygenation-metabolism interplay. Here, we present an integrated photoacoustic-metabolomic platform that combines high-resolution photoacoustic imaging with targeted metabolomics to comprehensively assess cerebral oxygenation and metabolic alterations during sepsis. Our imaging system provides high spatiotemporal resolution, enabling mapping of key parameters, including cerebral oxygen saturation (sO2), oxygen extraction fraction (OEF), and the spatial heterogeneity of oxygen metabolism. By integrating these imaging capabilities with region-specific metabolomic profiling, we uncover a dynamic relationship between sepsis-driven oxygenation disruptions and metabolic reprogramming. Specifically, we demonstrate that sepsis induces heterogeneous cortical hypoxia, dysregulated OEF dynamics, and a metabolic shift marked by enhanced glycolysis and suppressed pentose phosphate pathway activity in high-OEF regions. This multimodal platform not only advances our understanding of the pathophysiology of SIBD but also offers a powerful tool for early diagnosis, personalized therapeutic strategies, highlighting the promise in bedside monitoring and precision medicine applications in sepsis management.

28 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
XXXiaoyong Xiao
Xiaoyong Xiao
XHXiaoran Huang
Xiaoran Huang
FSFeier Song
Feier Song
GCGuona Chen
Guona Chen
YZYuelin Zhang
Yuelin Zhang
XLXin Li
Xin Li
OBJECTIVE: Evidence from previous studies has demonstrated that NRF2 can protect cardiovascular progression,which prompted us to study if NRF2 is involved in AAA development. APPROACH AND RESULTS: The difference and function of NRF2 in AAA were verified on human aortic tissues combined with scRNA-seq samples.We then used angiotensin II (Ang II) infusion mouse model with VSMCs-specific knockout to study the role of NRF2 in AAA formation.Primary cultured VSMCs were used to study how NRF2 regulates contractile VSMCs phenotype.Patient specimens were obtained to investigate the relevance of NRF2 expression to human AAA disease. NRF2 was induced in abdominal aortic VSMCs in both mouse and human AAA tissues. VSMCs-specific NRF2 knockout increased experimental AAA formation. Mechanistically, NRF2 regulates the contractile VSMCs phenotypic through miRNA145, leading to increased classic contractile protein level to prevent the development of AAA. CONCLUSIONS: NRF2 is a negative regulator of AAA development, and thus may represent a potentially new therapeutic target to inhibit AAA growth and rupture.